Once diagnosed with depression, patients frequently face the question: "Are you interested in therapy, medications or both?"
As a resident physician in psychiatry, I've seen many patients grapple with this question; the most frequent answer I've heard from patients is "I'm not sure." Deciding between different types of medical treatment can be challenging, especially amid the fog of depression. Moreover, patients rely on doctors to help guide them, and we're often not sure ourselves which is the best approach for a specific patient.
People commonly associate psychotherapy with Freud and couches, but newer, evidence-based treatments such as cognitive behavioral therapy have become prominent in the field. CBT helps patients develop strategies to address harmful thoughts, emotions and behaviors that may contribute to depression.
There are many proposed explanations for how specific psychotherapies treat depression. These possibilities include giving patients social support and teaching coping skills, and researchers are using neuroimaging to study how these treatments affect depressed patients' brains.
Antidepressant medications are thought to work by changing chemical signaling in our brains. For example, one class of commonly used drugs — selective serotonin reuptake inhibitors — is designed to alter levels of the neurotransmitter serotonin in the brain. These antidepressants may be effective for treating depression in some patients, but the neurochemistry of depression remains poorly understood, and we're still not entirely sure how these drugs alleviate depressive symptoms.
A number of recent studies highlight the uncertainty involved with these treatment decisions. Researchers have dedicated considerable effort to studying the relative effectiveness between psychotherapies and antidepressants, frequently without finding much difference. For instance, a study published in 2012 reviewed data from more than 100 prior trials and included more than 10,000 patients; although psychotherapies and antidepressants each worked better than placebo in blinded trials at reducing depressive symptoms, neither of these treatments was more effective than the other. Furthermore, psychotherapies and antidepressants did no better overall than alternative therapies such as exercise.
In 2014, research presented at the European Congress of Psychiatry suggested that CBT was just as good as, if not better than, antidepressants for the acute treatment of depression. A 2015 systematic review of randomized trials similarly found that antidepressants were no better than CBT across multiple measures for managing depression. And this year, a meta-analysis looking at dozens of studies found psychotherapies and medications were fairly alike at improving quality of life and functioning in people with depression.
If psychotherapy and medication are both used to treat depression, could using them together work even better?
This is a valid question, and one often brought up by patients. But the efficacy of combining these treatments is controversial in medical circles: Studies have come to different conclusions about it. As a result, many patients still receive one or the other first.
In 2016, the American College of Physicians released guidelines about using antidepressants as opposed to non-pharmacologic therapies for depression. After reviewing decades of evidence, a committee concluded that CBT and newer-generation antidepressants are "similarly effective treatments" for adults with major depression. The guidelines recommend that "clinicians select between either cognitive behavioral therapy or second-generation antidepressants" for treating patients with depression.
The authors of these guidelines also raise an important point: Doctors commonly turn first to antidepressants when treating patients with depression, even though evidence suggests alternate therapies are just as effective. The medications can also have side effects including nausea and vomiting as well as dangerous interactions with other drugs.
Antidepressants rank among the top-prescribed types of medications in the United States, and surveys suggest that more than 250 million antidepressant prescriptions are filled annually nationwide. A 2015 JAMA study found that 13 percent of American adults took antidepressants in 2012, a figure that nearly doubled since 1999.
Does this mean antidepressants are overprescribed?
It depends on how you interpret the question. Antidepressant use has risen considerably in recent years, while psychotherapy use appears to be stable or declining, because these treatments are often equally effective in managing depression, this might suggest we're relying more on these drugs.
Some patients may prefer to take medications for depression. Many people do not have the time to participate in psychotherapies like CBT or psychodynamic therapy — a type of talk therapy that explores the interplay between unconscious feelings and distressing symptoms — which can span multiple hour-long sessions over months. Others may not have access to mental-health specialists who can provide appropriate therapy. Then there are patients who would rather take a pill in the comfort of their own home, instead of opening up about intimate experiences in a doctor's office.
The structure of our health-care system may also be a factor. Higher insurance reimbursements for medications rather than psychotherapies may make physicians quicker to pull out the prescription pad. The crunched time and administrative burdens of today's medical practice can lead to pressured patient visits that are more conducive to quick check-ins and pills than to in-depth conversations.
Patients should be aware that there are treatment options in addition to therapy and medication. Several studies have shown that exercise may be helpful in managing mild to moderate depression. For patients with more severe depression, transcranial magnetic stimulation and electroconvulsive therapy — approaches that use brief electric currents to influence brain activity — can be lifesaving treatments.
As the ACP guidelines recommend, providers should discuss "treatment effects, adverse effect profiles, cost, accessibility, and preferences with the patient" when treating depression. But in today's hurried medical environment, completing that task in a thorough and comprehensive manner can often be difficult, if not impossible.
These technologies have shown promise, but they remain far from standard clinical practice. And adding more tests to doctors' visits may ignore the central issue when treating depression: Do we have enough time to truly talk with our patients about their options?
Morris is a resident physician in psychiatry at the Stanford University School of Medicine.